Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study.

• Main Authors: Christine L Dubray (Author), Anita D Sircar (Author), Valery Madsen Beau de Rochars (Author), Joshua Bogus (Author), Abdel N Direny (Author), Jean Romuald Ernest (Author), Carl R Fayette (Author), Charles W Goss (Author), Marisa Hast (Author), Kobie O'Brian (Author), Guy Emmanuel Pavilus (Author), Daniel Frantz Sabin (Author), Ryan E Wiegand (Author), Gary J Weil (Author), Jean Frantz Lemoine (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2020-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In Haiti, 22 communes still require mass drug administration (MDA) to eliminate lymphatic filariasis (LF) as a public health problem. Several clinical trials have shown that a single oral dose of ivermectin (IVM), diethylcarbamazine (DEC) and albendazole (ALB) (IDA) is more effective than DEC plus A...